Syndax Pharmaceuticals Inc. (SNDX)
$20.82
$0.28
(1.34%)
As on 08-May-2026 10:38EDT
Market cap
$1,830 Mln
Revenue (TTM)
$217 Mln
P/E Ratio
--
P/B Ratio
42.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-105.3
-
Debt to Equity
8.3
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
88,514,286
10 Years Aggregate
CFO
$-554.90 Mln
EBITDA
$-709.01 Mln
Net Profit
$-680.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals (SNDX)
| -0.9 | -15.5 | 3.3 | 108.4 | 1.2 | 5.3 | 3.7 |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals (SNDX)
| 58.9 | -38.6 | -15.1 | 16.3 | -1.6 | 153.3 | 97.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syndax Pharmaceuticals (SNDX)
|
20.8 | 1,829.8 | 217.2 | -243.3 | -31.2 | -309.8 | -- | 42.5 |
| 27.8 | 1,604.5 | 66.1 | -422.6 | -720.0 | -35.3 | -- | 0.7 | |
| 7.1 | 1,753.9 | 427.7 | -58.1 | -9.0 | -38.3 | -- | 12.2 | |
| 21.7 | 1,082.3 | 412.8 | -8.2 | -2.6 | -2.6 | -- | 3.5 | |
| 18.2 | 498.0 | 42.5 | -162.1 | -374.6 | -107.9 | -- | 2.7 | |
| 14.4 | 908.8 | 0.0 | -69.7 | -- | -33.4 | -- | 3.8 | |
| 86.4 | 7,095.5 | 51.5 | -315.1 | -477.7 | -25.3 | -- | 4.5 | |
| 425.4 | 12,189.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.9 | 19.9 | |
| 12.2 | 1,010.5 | 204.9 | -157.3 | -39.6 | -- | -- | 25.4 | |
| 31.5 | 3,747.9 | 0.0 | -472.3 | -- | -77.8 | -- | 7.3 |
Shareholding Pattern
View DetailsAbout Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R... acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. Address: 730 Third Avenue, New York, NY, United States, 10017 Read more
-
CEO & Director
Mr. Michael A. Metzger M.B.A.
-
CEO & Director
Mr. Michael A. Metzger M.B.A.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Syndax Pharmaceuticals (SNDX)
What is the current share price of Syndax Pharmaceuticals Inc (SNDX) Today?
The share price of Syndax Pharmaceuticals Inc (SNDX) is $20.82 (NASDAQ) as of 08-May-2026 10:38 EDT. Syndax Pharmaceuticals Inc (SNDX) has given a return of 1.24% in the last 3 years.
What is the current PB & PE ratio of Syndax Pharmaceuticals Inc (SNDX)?
Since, TTM earnings of Syndax Pharmaceuticals Inc (SNDX) is negative, P/E ratio is not available.
The P/B ratio of Syndax Pharmaceuticals Inc (SNDX) is 42.49 times as on 07-May-2026, a 855 premium to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.40
|
28.28
|
|
2024
|
-3.57
|
3.95
|
|
2023
|
-7.23
|
2.73
|
|
2022
|
-10.80
|
3.32
|
|
2021
|
47.42
|
2.89
|
What is the 52 Week High and Low of Syndax Pharmaceuticals Inc (SNDX)?
The 52-week high and low of Syndax Pharmaceuticals Inc (SNDX) are Rs 25.59 and Rs 8.58 as of 08-May-2026.
What is the market cap of Syndax Pharmaceuticals Inc (SNDX)?
Syndax Pharmaceuticals Inc (SNDX) has a market capitalisation of $ 1,830 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Syndax Pharmaceuticals Inc (SNDX)?
Before investing in Syndax Pharmaceuticals Inc (SNDX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.